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Gai-qin Pei8, Xia Qiu8 & Ke-hu Yang2,3
Because of the methodological complexity of network meta-analyses (NMAs), NMAs may be more 
vulnerable to methodological risks than conventional pair-wise meta-analysis. Our study aims to 
investigate epidemiology characteristics, conduction of literature search, methodological quality and 
reporting of statistical analysis process in the field of cancer based on PRISMA extension statement and 
modified AMSTAR checklist. We identified and included 102 NMAs in the field of cancer. 61 NMAs were 
conducted using a Bayesian framework. Of them, more than half of NMAs did not report assessment of 
convergence (60.66%). Inconsistency was assessed in 27.87% of NMAs. Assessment of heterogeneity 
in traditional meta-analyses was more common (42.62%) than in NMAs (6.56%). Most of NMAs did not 
report assessment of similarity (86.89%) and did not used GRADE tool to assess quality of evidence 
(95.08%). 43 NMAs were adjusted indirect comparisons, the methods used were described in 53.49% 
NMAs. Only 4.65% NMAs described the details of handling of multi group trials and 6.98% described 
the methods of similarity assessment. The median total AMSTAR-score was 8.00 (IQR: 6.00–8.25). 
Methodological quality and reporting of statistical analysis did not substantially differ by selected 
general characteristics. Overall, the quality of NMAs in the field of cancer was generally acceptable.
Cancer is a leading cause of death worldwide and the total number of global cancer deaths is projected to increase 
by 45% from 7.9 million in 2007 to 11.5 million in 20301. For patients suffering from cancer, healthcare inter-
ventions aim to cure or considerably prolong the life of patients and to ensure the best possible quality of life 
for cancer survivors1. Treatment decisions should be based on evidence of the existing most effective treatment 
given available resources. High quality systematic reviews/meta-analyses of randomized controlled trials (RCTs) 
can provide the most valid evidence2. However, conventional meta-analysis becomes inadequate when there are 
no head-to-head trials comparing alternative interventions, or when more than two interventions need to be 
compared simultaneously3. For example, although there are trials directly comparing each of the newer antineo-
plastic agents with the current standard treatment (or placebo) for patients with neoplasm, there are no trials that 
directly compared different newer antineoplastic agents. Another example is a lack of direct comparison of 19 
different chemotherapy regimens that are currently available for the treatment of advanced pancreatic cancer4.
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Network meta-analyses (NMAs), as a generalization of pairwise meta-analysis, is becoming increasingly 
popular5–8. In the absence of or insufficient head-to-head comparisons of competing interventions of interest, 
NMAs using indirect treatment comparison analyses can provide useful evidence to inform health-care decision 
making. Even when evidence from direct comparisons are available, combining them with indirect estimates in a 
mixed treatment comparison may yield more refined estimates8,9. Formally, NMAs can be defined as a statistical 
combination of all available evidence for an outcome from several studies across multiple treatment to generate 
estimates of pairwise comparisons of each intervention to every other intervention within a network10. It has been 
considered that NMAs would be the next generation evidence synthesis toolkit which, when properly applied, 
could serve decision-making better than the conventional pair-wise meta-analysis11. However, NMAs are subject 
to similar methodological risks as standard pairwise systematic reviews. Because of its methodological complex-
ity, it is probable that NMAs may be more vulnerable to such risks12. Therefore, it is important to assess the quality 
of published NMAs before their results are implemented into clinical or public health practice.
Previous studies have examined methodological problems in published indirect comparisons and NMAs, 
especially regarding reporting quality of statistical analysis12–15. It was concluded that the key methodological 
components of the NMAs process were often inadequately reported in published NMAs12. Currently, there are 
30 tools available to assess the methodological quality of systematic reviews or meta-analyses16. To the best of 
our knowledge, no standard tool has been developed currently to assess the methodological quality of NMAs. 
AMSTAR (a measurement tool to assess the methodological quality of systematic reviews) tool is probably the 
most commonly used quality assessment tool for systematic reviews, which has been proven with good reliability, 
validity, and responsibility17–19.
The objective of this study is to conduct a methodological review of published NMAs in the field of cancer, 
summarise their characteristics, methodological quality, and reporting of key statistical analysis process. We also 
aim to compare the methodological quality and reporting of statistical analysis by selected general characteristics.
Results
Search results. Initial literature search retrieved 6,408 citations. Of them, 3,754 citations were duplicates, 
so 2,654 citations were sent for further screening. Based on titles and abstracts, 1,741 citations were excluded. 
Then 637 articles were excluded based on reading full-texts, for reasons including: traditional pair-wise meta 
analysis (n = 64), methodological studies (n = 67), NMAs not related to cancer (n = 478), abstracts/letters/edito-
rials/correspondences (n = 26), cost-effectiveness reviews (n = 6). Finally, 102 NMAs in the field of cancer were 
included (Fig. 1), including 92 published in English and 10 in Chinese. A list of included NMAs could be found 
in Appendix 1.
General characteristics of included NMAs. The first NMA in the field of cancer was published in 200620. 
The number of published NMAs increased slowly until 2010, and then increased quickly. 43.14% (44/102) of the 
included NMAs were published since 2014 (Fig. 2). 98 NMAs involved 24 kinds of cancer, although 4 NMAs did 
not specify types of cancer. Non-small cell lung cancer (19/102, 18.63%) and breast cancer (12/102, 11.76%) were 
the most or secondly common type of cancer studies in the included NMAs (Fig. 3). NMAs were often performed 
by researchers based in China (29/102, 28.43%), UK (24/102, 23.53%), and USA (11/102, 10.78%) (Fig. 4). 99 
NMAs were published in 60 different journals and 3 NMAs were doctorate dissertations. 85.30% (87/102) of 
NMAs were indexed by Science Citation Index (SCI) and 31.37% (32/102) were published in journals with high 
impact factors. According to 56 NMAs (54.90%) that reported dates of manuscript reception and acceptation, the 
median publishing period was 101 days (IQR: 47–187 days). According to 60 NMAs (58.82%) with information 
on funding source, 46 NMAs (45.10%) received funding support. The median number of interventions assessed 
per NMA was five (IQR: 3–9). The median number of trials included per NMAs was 12 (IQR: 7–23), and the 
median number of patients included in NMAs was 3,605 (IQR: 1,950–7,564). The main characteristics of the 
included NMAs were shown in Table 1. A more detailed characteristics and reporting of statistical analysis pro-
cess could be found in Appendix 2.
Reporting of literature search. Thirteen NMAs did not report any information on literature search, 
whereas one NMAs was conducted based on previous meta-analyses without additional searching. 98.90% 
(88/89) NMAs searched only English databases. The median number of Chinese databases searched was 5 (IQR: 
3–6), and it was 3 (IQR: 3–4) for English databases. 22.50% (20/89) NMAs reported the search strategy, and the 
median number of search strategies reported was 2 (IQR: 1–3). 27.00% (24/89) NMAs searched previous pub-
lished meta-analyses as a supplemental literature search. Other supplemental literature search methods included 
reference list checking, clinical trial registration platform, conference abstracts or web sites, and google engine 
(Table 2). PubMed/MEDLINE was the most common single database searched, and it was often combined with a 
search of Cochrane Library. The details of databases searched were showed in Table 3.
Reporting of statistical analysis processes. Sixty-one (59.80%) NMAs were conducted using a Bayesian 
framework (2 reviews are adjusted indirect comparisons). 43 reviews were adjusted indirect comparisons (2 
adjusted indirect comparisons use Bayesian framework).
For NMAs using a Bayesian framework, more than half also included traditional meta-analyses (42/61, 
68.85%). The majority of NMAs reported summary measures (57/61, 93.44%). 75.41% (46/61) NMAs reported 
the model used. Of the 24 (24/61, 39.34%) NMAs that tested model fit, the most common method was the use 
of deviance information criterion (15/24, 62.50%). The majority of NMAs (40/61, 65.57%) did not make their 
code available to journal readers. 16 (26.23%) NMAs provided the model source cited, however, it was unclear 
for the details of model used. 91.80% (56/61) did not report whether there was an adjustment for multiple arms. 
Half of NMAs (31/61, 50.82%) specified the prior distributions used, and the most common prior used was 
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non-informative prior (18/31, 58.06%). Only 4 (6.56%) NMAs performed pre-specified sensitivity analyses. More 
than half of NMAs did not report assessment of convergence (37/61, 60.66%) and sensitivity analyses performed 
(37/61, 60.66%). Inconsistency was assessed in 27.87% of NMAs. Assessment of heterogeneity in traditional 
meta-analyses was more common (26/61, 42.62%) than in NMAs (4/61, 6.56%). Most of the included NMAs did 
not report assessment of similarity (53/61, 86.89%), publication or reporting bias (60/61, 98.36%), subgroup anal-
yses or meta-regression performed (49/61, 80.33%), and whether GRADE tool was used to assess quality of evi-
dence (58/61, 95.08%). NMAs published in journals with higher impact factors more often provided model code 
Figure 1. The details of literature selection. 
Figure 2. The trend of year of publications. 
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(57.69% versus 23.08%, p = 0.012) and assessed the heterogeneity of NMAs (0% versus 15.38%, p = 0.039). Based 
on the median division of the number of included NMAs, we chose December 31st 2013 as cut-off point. NMAs 
published prior to December 31st 2013 more often reported models used (89.66% versus 62.50%, p = 0.015), 
model code used (48.28% versus 21.88%, p = 0.032), and assessment of heterogeneity of NMAs (13.79% versus 
0%, p = 0.031). Other results did not differ by journal impact factor or year of publication. The more details of 
statistical reporting in Bayesian NMAs was showed in Table 4.
For adjusted indirect comparisons, the majority of NMAs (42/43, 97.67%) also conducted traditional 
meta-analyses and 53.49% (23/43) adjusted indirect comparisons were performed using methods described by 
Bucher21. 58.14% (25/43) assessed the heterogeneity of direct comparisons, but none of NMAs assessed the het-
erogeneity of indirect comparisons. Only two (4.65%) NMAs described the details of handling of multi group 
trials and three (6.98%) described the methods of similarity assessment. Most of NMAs did not report whether 
sensitivity analyses were performed (38/43, 88.37%) and whether subgroup analyses or meta-regression were 
Figure 3. Categories of disease of included NMAs. 
Figure 4. Countries of included NMAs. 
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performed (34/43, 79.07%). These results did not differ by journal quality or year of publication. The details of 
statistical reporting for adjusted indirect comparisons was showed in Table 5.
Methodological quality assessment. The results of methodological quality assessment based on modi-
fied AMSTAR checklist were presented in Fig. 5. The median total score was 8.00 (IQR: 6.00–8.25). Approximately 
half of the included NMAs did not perform a comprehensive literature search (Item 3, 42.31%). More than half 
of NMAs (69.61%) did not consider the scientific quality of the included studies in formulating conclusions, and 
84.31% NMAs did not assess the likelihood of publication bias.
Table 6 presented the results of stratified analyses of methodological quality assessment. NMAs published 
in journals with higher impact factors more often performed a comprehensive literature search (78.13% versus 
45.45%, p = 0.002), reported appropriate methods used to combine the findings of studies (81.25% versus 58.18%, 
p = 0.019), and assessed the likelihood of publication bias (25.00% versus 5.45%, p = 0.017). NMAs published 
after December 31st 2013 more often assessed the scientific quality of the included studies (86.36% versus 55.17%, 
p = 0.001) and considered the scientific quality in formulating conclusions (43.18% versus 20.69%, p = 0.015). 
Most of these items did not differ between funding support and non-funding support. NMAs published in China 
more often reported two independent reviewers for study selection and data extraction (89.66% versus 65.75%, 
p = 0.015), assessed the scientific quality of the included studies (86.21% versus 61.64%, p = 0.016) and consid-
ered the scientific quality in formulating conclusions (68.97% versus 15.07%, p = 0.000). Moreover, Bayesian 
NMAs more often reported two independent reviewers for study selection and data extraction (81.97% versus 
60.47%, p = 0.015), performed a comprehensive literature search (70.49% versus 39.53%, p = 0.002), considered 
the status of publication (i.e. grey literature) used as an inclusion criterion (86.89% versus 67.44%, p = 0.017), and 
assessed the scientific quality of the included studies (78.69% versus 55.81%, p = 0.013).
Category Frequency Proportion [%(95% CI)]
Language (n = 102)
English 92 90.20 (82.70–94.60)
Chinese 10 9.80 (5.40–17.30)
Journal quality (n = 102)
SCI 87 85.30 (77.00–90.90)
Non-SCI 15 14.70 (9.10–23.00)
CSCD 3 2.90 (1.00–8.70)
Non-CSCD 7 6.90 (3.30–13.70)
Impact factor (n = 87)
Median (IQR) 3.94 (2.721–5.635)
0.0–2.0 6 6.90 (3.10–14.50)
2.0–5.0 49 56.30 (45.80–66.30)
5.0–10.0 22 25.30 (17.30–35.40)
≥ 10.0 10 11.50 (6.30–20.10)
Publishing period (n = 56)
Median (IQR) 101 (47–187) day
1–30 days 12 21.40 (12.60–34.10)
30–60 days 10 17.90 (9.90–30.10)
60–90 days 4 7.10 (2.70–17.50)
90–150 days 12 21.40 (12.60–34.10)
≥ 150 days 19 33.90 (22.80–47.20)
Funding source (n = 60)
Unfunded (n = 14) 14 23.30 (14.30–35.60)
Industry-supported (n = 20) 20 33.30 (22.60–46.10)
Government-supported (n = 23) 23 38.30 (27.00–51.10)
Industry + Government (n = 3) 3 5.00 (1.60–14.40)
Number of author Median (IQR) 6 (5–8)
Type of included study (n = 102)
RCT 100 98.00 (92.50–99.50)
Meta-analysis 2 2.00 (0.50–7.50)
Number of included trial Median (IQR) 12 (7–23)
Intervention Median (IQR) 5 (3–9)
Sample size (n = 102)
Median (IQR) 3605 (1950–7564)
Not reported 7 6.90 (3.30–13.70)
Outcome (n = 102)
Median (IQR) 3 (2–5)
Dichotomous 73 71.60 (62.10–79.50)
Continue 5 4.90 (2.10–11.20)
Survival time 79 77.50 (68.30–84.50)
Number of study arm (n = 102)
Two arms 50 49.00 (39.50–58.60)
Three arms 7 6.90 (3.30–13.70)
Two + Three arms/more 36 35.30 (26.70–45.00)
Table 1.  Characteristics of the included NMA. Note: CI, confidence interval; NMA, network meta-analysis; 
SCI, Science Citation Index; CSCD, Chinese Science Citation Database; IQR, interquartile range.
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Table 7 presented the association of total AMSTAR-score and selected general characteristics. Although the 
AMSTAR-score of NMAs published in China was higher than NMAs published in others (p = 0.023), there were 
no significant differences between AMSTAR-score and different countries (p = 0.465). The differences were not 
significant between AMSTAR-score and other selected general characteristics.
Discussion
We identified 102 NMAs involving 24 kinds of cancer. Methodological quality and statistical reporting were 
assessed based on PRISMA extension statement and modified AMSTAR checklist. In addition, we also assessed 
the conduct of literature search in the included NMAs. Some key methodological components including the liter-
ature search and statistical analysis were missing or inadequate in most of included NMAs, such as only 22.50% of 
NMAs reported search strategy, 6.56% assessed the heterogeneity in NMAs. Methodological quality and report-
ing of statistical analysis did not substantially differ by selected general characteristics of NMAs.
NMAs could provide useful evidence on relative effectiveness of different interventions for decision-making 
when there are no or insufficient direct comparison trials11. Methodological quality of NMAs is a crucial point 
for health care decision-makers and researchers. We assessed the methodological quality of NMAs in the field of 
cancer based on modified AMSTAR checklist. Some methodological flaws were identified, especially regarding 
Category Frequency Proportion [%(95% CI)]
Reported database searched (n = 102) Yes 89 87.30 (79.30–92.50)
Language of database searched (n = 89)*
English 88 98.90 (92.50–99.80)
Chinese 10 11.20 (6.20–19.60)
Chinese + English 9 10.10 (5.30–18.30)
Number of Chinese database searched Median (IQR) 5(3–6)
Number of English database searched Median (IQR) 3(3–4)
Number of search strategy Median (IQR) 2(1–3)
Reported search strategy (n = 89) Yes 20 22.50 (15.00–32.30)
Presented search strategy (n = 20)
Manuscript 9 45.00 (25.30–66.40)
Supplement 5 25.00 (10.80–47.80)
Online supplement 6 30.00 (14.10–52.70)
Searched previous published meta analysis (n = 89) Yes 24 27.00 (18.80–37.10)
Supplemental literature search (n = 89) Yes 75 84.30 (75.20–90.50)
Supplemental literature search method (n = 75)
Reference lists checking 42 56.00 (44.70–66.80)
Clinical trial registration platform 27 36.00 (26.00–47.40)
Conference abstracts or Web sites 43 57.30 (46.00–68.00)
Google engine 17 22.70 (14.60–33.50)
Table 2.  Reporting information of literature search. *13 studies did not search databases. CI, confidence 
interval; IQR, interquartile range.
Category Frequency Proportion [%(95% CI)]
Name of database
PubMed/MEDLINE 84 94.40 (87.20–97.60)
EMBASE 69 77.50 (67.70–85.00)
The Cochrane Library 71 79.80 (70.20–86.90)
ISI Web of Knowledge 17 19.10 (12.20–28.60)
CNKI 9 10.10 (5.30–18.30)
CBM 9 10.10 (5.30–18.30)
Wanfang 7 7.90 (3.80–15.60)
VIP 8 9.00 (4.60–17.00)
CSCD 7 7.90 (3.80–15.60)
Others 35 39.30 (29.80–49.80)
Common combination of 
database
PubMed/MEDLINE + EMBASE 65 73.00 (62.90–81.20)
PubMed/MEDLINE + Cochrane 69 77.50 (67.70–85.00)
EMBASE + Cochrane 60 67.40 (57.00–76.30)
PubMed/MEDLINE + EMBASE + Cochrane 56 62.90 (52.50–72.30)
PubMed/MEDLINE + ISI Web of Knowledge 17 19.10 (12.20–28.60)
PubMed/MEDLINE + EMBASE + Cochrane + ISI Web of Knowledge 14 15.70 (9.50–24.80)
PubMed/MEDLINE + EMBASE + CBM 8 9.00 (4.60–17.00)
PubMed/MEDLINE + CNKI 7 7.90 (3.80–15.60)
Table 3.  Information of databases searched (n = 89).
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to literature search (Item 3), assessment of scientific quality (Item 7) and scientific quality used appropriately in 
formulating conclusions (Item 8), the methods used to combine the findings of studies (Item 9), and assessment 
of publication bias (Item 10).
Items
All studies 
(n = 61)
Journal impact factor* Year of publication
Low (<5.00) 
(n = 26)
High (≥5.00) 
(n = 26) P-value
Older studies 
(~2013) (n = 29)
Recent studies 
(2014~2015) (n = 32) P-value
Was traditional meta-analysis conducted? (Yes) 42/61(68.85) 15/26(57.69) 20/26(76.92) 0.143 18/29(62.07) 24/32(93.10) 0.280
Were summary measures reported? (Yes) 57/61(93.44) 24/26(92.31) 25/26(96.15) 0.556 27/29(93.10) 30/32(93.75) 0.920
Planned methods of analysis:
 What was the model used?
  Fixed-effect 7/46(15.22) 4/20(20.00) 2/24(8.33) 0.267 6/26(23.08) 1/20(5.00) 0.094
  Random-effects 11/46(23.91) 4/20(20.00) 6/24(25.00) 0.697 6/26(23.08) 5/20(25.00) 0.881
  Fixed- and random-effects 18/46(39.13) 12/20(60.00) 6/24(25.00) 0.020 7/26(26.92) 11/20(55.00) 0.056
  Other models 10/46(21.74) 0/20(0.00) 10/24(41.67) 0.001 7/26(26.92) 3/20(15.00) 0.336
  Nor reported 15/61(24.59) 6/26(23.08) 2/26(7.69) 0.128 3/29(10.34) 12/32(37.50) 0.015
 How to present the model code?
  Supplement 5/21(23.81) 2/6(33.33) 3/15(20.00) 0.527 2/14(14.29) 3/7(42.86) 0.157
  Reference 16/21(76.19) 4/6(66.67) 12/15(80.00) 0.527 12/14(85.71) 4/7(57.14) 0.157
  Not provided 40/61(65.57) 20/26(76.92) 11/26(42.31) 0.012 15/29(51.72) 25/32(78.13) 0.032
 How to assess the model fit?
  Residual deviance 2/24(8.33) 1/14(7.14) 1/10(10.00) 0.807 1/9(11.11) 1/15(6.67) 0.709
  Deviance information criterion 15/24(62.50) 8/14(57.14) 7/10(70.00) 0.530 6/9(66.67) 9/15(60.00) 0.749
  Residual deviance+ Deviance information criterion 7/24(29.17) 5/14(35.71) 2/10(20.00) 0.414 2/9(22.22) 5/15(33.33) 0.570
  Not reported 37/61(60.66) 12/26(46.15) 16/26(61.54) 0.270 20/29(68.97) 17/32(53.13) 0.210
  Was handling of multigroup trials reported? (Yes) 5/61(8.20) 1/26(3.85) 3/26(11.54) 0.303 3/29(10.34) 2/32(6.25) 0.564
 Were the prior distributions reported?
  Noninformative prior 18/31(58.06) 9/13(69.23) 10/17(58.82) 0.564 8/16(50.00) 10/15(66.67) 0.355
  Informative prior 3/31(9.68) 1/13(7.69) 2/17(11.76) 0.717 1/16(6.25) 2/15(13.33) 0.512
  Vague prior 10/31(32.26) 4/13(30.77) 6/17(35.29) 0.798 7/16(43.75) 3/15(20.00) 0.164
  Not specified 30/61(49.18) 13/26(50.00) 9/26(34.62) 0.266 13/29(44.83) 17/32(53.13) 0.521
  Sensitivity analysis based on priors 4/61(6.56) 2/26(7.69) 2/26(7.69) 1.000 2/29(6.90) 2/32(6.25) 0.920
 Was the convergence assessed?
  Not reported 37/61(60.66) 15/26(57.69) 14/26(53.85) 0.782 17/29(58.62) 20/32(62.50) 0.759
  Gelman Rubin statistic 21/24(87.50) 11/11(100.00) 10/12(83.33) 0.166 9/12(75.00) 12/12(100.00) 0.070
  Visual plot inspection 13/24(54.17) 5/11(45.45) 7/12(58.33) 0.546 7/12(58.33) 6/12(50.00) 0.688
  Observation of chain mix 2/24(8.33) 2/11(18.18) 0/12(0.00) 0.131 1/12(8.33) 1/12(8.33) 1.000
 Was the heterogeneity in NMA assessed?
  Precision (Tau2) 4/61(6.56) 0/26(0.00) 4/26(15.38) 0.039 4/29(13.79) 0/32(0.00) 0.031
  Not reported 57/61(93.44) 26/26(100.00) 22/26(84.62) 0.039 25/29(86.21) 32/32(100.00) 0.031
 Was the similarity in NMA assessed?
  Not reported 53/61(86.89) 22/26(84.62) 22/26(84.62) 1.000 23/29(79.31) 30/32(93.75) 0.098
  Comparing patients’ or trials’ characteristics 5/8(62.50) 2/4(50.00) 3/4(75.00) 0.495 4/6(66.67) 1/2(50.00) 0.693
  Investigating potential effect modifying covariates 3/8(37.50) 2/4(50.00) 1/4(25.00) 0.495 2/6(33.33) 1/2(50.00) 0.693
Were the inconsistency assessed?
 Not reported 44/61(72.13) 20/26(76.92) 16/26(61.54) 0.234 20/29(68.97) 24/32(75.00) 0.603
 Inconsistency/incoherence factors 4/17(23.53) 1/6(16.67) 2/10(20.00) 0.873 3/9(33.33) 1/8(12.50) 0.327
 Hypothesis test 8/17(47.06) 2/6(33.33) 6/10(60.00) 0.317 4/9(44.44) 4/8(50.00) 0.824
 Node-splitting analysis 5/17(29.41) 3/6(50.00) 2/10(20.00) 0.225 2/9(22.22) 3/8(37.50) 0.503
Was the publication or reporting bias assessed?
 Comparison-adjusted funnel plot 1/61(1.64) 0/26(0.00) 1/26(3.85) 0.317 0/29(0.00) 1/32(3.13) 0.341
 Not reported 60/61(98.36) 26/26(100.00) 25/26(96.15) 0.317 29/29(100.00) 31/32(96.87) 0.341
Additional analyses:
 Was a sensitivity analysis performed? (Yes) 24/61(39.34) 10/26(38.46) 12/26(46.15) 0.578 12/29(41.38) 12/32(37.50) 0.759
 Was subgroup analysis or meta-regression 
performed? (Yes) 12/61(19.67) 3/26(11.54) 7/26(26.92) 0.163 7/29(24.14) 5/32(15.63) 0.407
 Was the GRADE used? (Yes) 3/61(4.92) 1/26(3.85) 2/26(7.69) 0.556 2/29(6.90) 1/32(3.13) 0.500
Table 4.  Statistical Reporting in Bayesian analysis [n/N(%)]. *9 studies published in journals with no 
associated impact factor.
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NMAs aimed to rank the benefits (or harms) of interventions, based on all available RCTs. Thus, the identifi-
cation of all relevant data is critical7. Most of the included NMAs (80.39%, 82/102) did not report database search 
strategy. For those that reported search strategy, 26.96% only searched previous published meta-analyses. It is 
important to search, track, and include previous systematic reviews and meta-analyses in conducting NMAs22. 
PubMed/MEDLINE was the most commonly used databases and the most common combination of databases 
was PubMed/MEDLINE and EMBASE. The majority of NMAs did not search Chinese databases. Cohen et al.’ 
study showed that searching Chinese databases might lead to the identification of a large amount of additional 
clinical evidence, and suggested that Chinese biomedical databases should be searched when performing system-
atic reviews23.
The assessment of scientific quality of individual studies could affect findings of NMAs24. However, 31.37% 
of the included NMAs did not report methods for assessing the risk of bias of individual studies in methods 
sections. And 69.61% did not consider the scientific quality of the included studies in formulating conclusions. 
Although reporting bias could have a substantial effect on the conclusions of a NMA12, most of the included 
NMAs (84.31%) did not report a method to assess publication bias.
The complex nature of NMA mainly reflected in the diversification of interventions and complex statistical 
analysis process. Homogeneity and consistency assumptions underlie NMA25. Although assessment of hetero-
geneity in traditional meta-analyses was common, only 4 NMAs (3.92%) assessed the heterogeneity in the entire 
network by heterogeneity variance parameter (Tau2). Eleven (10.78%) explicitly reported the methods of assess-
ment of similarity. For those with Bayesian framework, 17 (27.87%) assessed the inconsistency between direct 
comparisons and indirect comparisons. GRADE tool was proposed to assess the quality of evidence from NMAs 
in 201426. However, it still was rarely used to assess quality of evidence in NMAs related to cancer.
To the best of our knowledge, this is the first review to comprehensively assess the methodological qual-
ity using a modified AMSTAR checklist, and simultaneously assess the quality of reporting of literature search 
and statistical analysis methods. Two recent reviews that also focused on the methodological problems of pub-
lished network meta analyses12,15 covered a wide range of medical areas and some details of reporting of literature 
search and statistical analysis were missing. Bafeta A et al.12 included 121 NMAs to examine the methodological 
reporting of NMAs, the results showed that 73% did not report the electronic search strategy for each database 
compared with 77.5% in our study. Most of NMAs did not assess quality of evidence using GRADE tool (3% vs. 
4.92%). The results of methodological reporting were similar to our study. Chambers J et al.15 also showed that 
there were similar methodological quality problems in their included NMAs. However, AMSTAR checklist has 
not been used to systematically assess the methodological quality of NMAs. Furthermore, we explored the poten-
tial factors influencing methodological quality and statistical reporting according to general characteristics of the 
included NMAs. There were no substantial differences by selected general characteristics of NMAs.
Our study also have some limitations. There was no standard tool to assess the methodological qual-
ity of NMAs. We slightly modified three of the 11 AMSTAR items (Item 1, Item 5, and Item 9) to assess the 
Items n/N
Journal impact factor (n = 37)* Year of publication (n = 43)#
Low (<5.00) 
(n = 29)
High (≥5.00) 
(n = 8) P-value
Older studies 
(~2013) (n = 31)
Recent studies 
(2014~2015) 
(n = 12) P-value
Was traditional meta-analysis conducted? (Yes) 42/43(97.67) 28/29(96.55) 8/8(100.00) 0.599 30/31(96.77) 12/12(100.00) 0.534
Were summary measures reported? (Yes) 41/43(97.62) 26/29(89.66) 8/8(100.00) 0.976 29/31(93.55) 12/12(100.00) 0.373
Planned methods of analysis in adjusted indirect comparisons:
 What was the method used?
  Bucher 23/28(82.14) 17/20(85.00) 2/4(50.00) 0.140 15/20(75.00) 8/8(100.00) 0.240
  Other methods 5/28(17.86) 3/20(15.00) 2/4(50.00) 0.123 5/20(25.00) 0/8(0.00) 0.125
  Not reported 15/43(34.88) 9/29(31.03) 4/8(50.00) 0.326 11/31(35.48) 4/12(33.33) 0.896
 Was the method presented or source cited?
  Manuscript 5/23(21.74) 1/16(6.25) 2/4(50.00) 0.033 4/20(20.00) 1/3(33.33) 0.610
  Reference 18/23(78.26) 15/16(93.75) 2/4(50.00) 0.033 16/20(80.00) 2/3(66.67) 0.610
  Not provided 20/43(46.51) 13/29(44.83) 4/8(50.00) 0.798 11/31(35.48) 9/12(75.00) 0.021
 Was handling of multigroup trials reported? (Yes) 2/43(4.65) 0/29(0.00) 1/8(12.50) 0.057 2/31(6.45) 0/12(0.00) 0.373
 Was the similarity assessed? 3/43(6.98) 3/29(10.34) 0/8(0.00) 0.349 3/31(9.68) 0/12(0.00) 0.269
 Was the inconsistency assessed?
  Not reported 36/43(83.72) 25/29(86.21) 5/8(62.50) 0.150 26/31(83.87) 10/12(83.33) 0.970
  Not application 4/7(57.14) 4/4(100.00) 0/3(0.00) 0.050 3/5(60.00) 1/2(50.00) 0.810
  Hypothesis test 3/7(42.86) 0/4(0.00) 3/3(100.00) 0.050 2/5(40.00) 1/2(50.00) 0.810
Additional analyses:
 Was a sensitivity analysis performed? 5/43(11.63) 1/29(3.45) 3/8(37.50) 0.007 3/31(9.68) 2/12(16.67) 0.526
 Was subgroup analysis or meta-regression performed? 9/43(20.93) 8/29(27.59) 1/8(12.50) 0.385 6/31(19.35) 3/12(25.00) 0.827
Table 5.  Statistical Reporting in adjusted indirect comparisons [n/N(%)]. *6 studies published in journals 
with no associated impact factor. #Based on the median division of number of included NMAs, December 31st 
2013 is the cut-off point.
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methodological quality of NMAs. However, there are still some problems or uncertain issues, such as the diffi-
culty in defining type of interventions and type of comparisons for inclusion in NMAs, how to draw geometry 
of the network, how to handle multi group trials, how to decide whether the assessment of similarity and con-
sistency was appropriate, and whether statistical analysis methods were appropriate for NMAs. The complex 
nature of statistical analysis of NMAs raised the necessity to develop a guideline about the reporting of statistical 
analysis of NMAs. As with other methodological studies, assessing methodological quality and reporting qual-
ity from published reports alone could be misleading. The study authors may have used adequate methods but 
omitted important details from published reports12, or published reports were sufficient referring to relevant 
reporting guidelines but not rigorous during the conduct process. For example, while we distinguished whether 
study selection and data extraction were performed by least two independent reviewers, we did not know whether 
the processes were really performed by two independent reviewers. Finally, we did not identify any eligible NMAs 
related to diagnostic test accuracy and animal study. We also did not include reviews based on individual patient 
data (IPD) due to the differences of method and statistical analysis processes between IPD and aggregated data.
Overall, the methodological quality of NMAs in the field of cancer was generally acceptable. However, some 
methodological flaws have been identified in published NMAs, especially regarding to literature search, assess-
ment of scientific quality and scientific quality used appropriately in formulating conclusions, the methods used 
to combine findings of studies, and assessment of publication bias. Methodological quality and statistical report-
ing did not substantially differ by general characteristics.
Methods
Search strategy. PubMed, EMBASE, Web of Science, Science Citation Index Expanded, Social Sciences 
Citation Index, The Cochrane Library, Cochrane Database of Systematic Reviews, Database of Abstracts of 
Reviews of Effects, Health Technology Assessment Database, NHS Economic Evaluation Database, Chinese 
Biomedical Literature Database (CBM), and China National Knowledge Infrastructure (CNKI) were searched 
from inception to February 26th, 2014. The search strategy was recently reported in a published paper7. All 
searches were updated on 9th July, 2015.
Eligibility criteria. We included any NMAs in the field of cancer in the English and Chinese languages, 
regardless of interventions. NMAs were defined as meta-analyses that used network meta-analytic methods to 
analyze, simultaneously, three or more different interventions7, adjusted indirect comparisons were also included. 
If the same NMA had duplicate publications, the latest was included. We excluded methodological articles, con-
ference abstracts, letters, editorials, correspondences, cost-effectiveness reviews, and reviews based on individual 
patient data.
Study selection. Literature search records were imported into ENDNOTE X6 literature management soft-
ware. Two independent reviewers (LG, LL) examined the title and abstract of retrieved studies to identify poten-
tially relevant studies according to the eligibility criteria. Then, full-text versions of all potentially relevant studies 
were obtained. Excluded trials and the reasons for their exclusion were listed, conflicts were resolved by a third 
reviewer (J-HT, or K-HY).
Figure 5. The results of methodological quality assessment. 
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Data extraction and management. A standard data abstraction form was created using Microsoft Excel 
2013 (Microsoft Corp, Redmond, WA, www.microsoft.com) to collect data of interest. A pilot-test was performed 
for literature selection and data extraction, and a “cheat sheet” with detailed definitions and examples were devel-
oped to ensure high inter-rater reliability among the reviewers.
General characteristics. The following general characteristics were collected by one reviewer (LG): first 
author, year of publication, country of corresponding author, journal name, publishing period (time from 
received to accepted), funding source (industry-supported, non-industry-supported, unfunded or not report), 
number of author, language of publication (English or Chinese), number and type of included original stud-
ies, sample size of included original studies, number of study arm, type of outcome (dichotomous, continue, 
or survival time), categories of disease, and number of interventions included in the network. We categorised 
journal types into Science Citation Index (SCI) or non-SCI; we also identified journals with high impact factors 
(IF ≥ 5.000, as reported on Journal Citation Reports 2014)27 or low impact factors (IF < 5.000). We also catego-
rised NMAs into older studies or recent studies based on the median division of number of included NMAs.
Reporting of literature search. One reviewer (XQ) extracted following information regarding reporting of 
literature search: number of databases searched (Chinese, English, or both), name of databases searched, whether 
the search strategy was provided, whether the previous systematic reviews/meta-analyses were searched, name 
and number of other sources searched (e.g., reference lists checking, clinical trial registration platform, confer-
ence abstracts or web sites, Google engine).
Reporting of statistical analysis processes. We assessed the reporting and quality of statistical analysis 
processes in the methods sections of each NMA report according to the Preferred Reporting Items for Systematic 
Reviews and Meta-analyses (PRISMA) extension statement for NMAs28. The following questions were designed 
Items (Yes)
All NMAs 
(n = 102)
Journal impact factor* Year of publication# Funding source
Country of 
corresponding author Type of NMAs
Low (<5.00) 
(n = 55) 
vs. High 
(≥5.00) 
(n = 32) P-value
Older 
(n = 58) 
vs. Recent 
(n = 44) P-value
Funding 
(n = 46) vs. 
Non-funding 
(n = 56) P-value
China 
(n = 29) 
vs. Others 
(n = 73) P-value
Bayesian NMAs 
(n = 61) vs. 
Adjusted indirect 
comparisons 
(n = 43)& P-value
Was the research 
question (i.e., research 
purpose, inclusion 
and exclusion criteria) 
clarified?
62/60.78 31/56.36 vs. 20/62.50 0.568
33/56.90 vs. 
29/65.91 0.358
26/56.52 vs. 
36/64.29 0.426
20/68.97 vs. 
42/57.53 0.288 38/62.30 vs. 25/58.14 0.671
Was there duplicate 
study selection and data 
extraction?
74/72.55 38/69.09 vs. 24/75.00 0.547
41/70.69 vs. 
33/75.00 0.631
32/69.57 vs. 
42/75.00 0.543
26/89.66 vs. 
48/65.75 0.015 50/81.97 vs. 26/60.47 0.015
Was a comprehensive 
literature search 
performed?
58/56.86 25/45.45 vs. 25/78.13 0.002
31/53.45 vs. 
27/61.36 0.426
26/56.52 vs. 
32/57.14 0.950
16/55.17 vs. 
42/57.53 0.829 43/70.49 vs. 17/39.53 0.002
Was the status of 
publication (i.e. grey 
literature) used as an 
inclusion criterion?
81/79.41 43/78.18 vs. 26/81.25 0.728
46/79.31 vs. 
35/79.55 0.977
35/76.09 vs. 
46/82.14 0.454
26/89.66 vs. 
55/75.34 0.109 53/86.89 vs. 29/67.44 0.017
Was a list of included 
studies provided? 94/92.16
50/90.91 vs. 
29/90.63 0.965
53/91.38 vs. 
41/93.18 0.739
44/95.65 vs. 
50/89.29 0.236
28/96.55 vs. 
66/90.41 0.300 56/91.80 vs. 40/93.02 0.819
Were the characteristics 
of the included studies 
provided?
100/98.04 54/98.18 vs. 31/96.88 0.715
58/100.00 vs. 
42/95.45 0.103
45/97.83 vs. 
55/98.21 0.889
29/100.00 vs. 
71/97.26 0.370
59/96.72 vs. 
43/100.00 0.233
Was the scientific 
quality of the included 
studies assessed and 
documented?
70/68.63 34/61.82 vs. 25/78.13 0.098
32/55.17 vs. 
38/86.36 0.001
29/63.04 vs. 
41/73.21 0.273
25/86.21 vs. 
45/61.64 0.016 48/78.69 vs. 24/55.81 0.013
Was the scientific quality 
of the included studies 
used appropriately in 
formulating conclusions?
31/30.39 11/20.00 vs. 8/25.00 0.584
12/20.69 vs. 
19/43.18 0.015
9/19.57 vs. 
22/39.29 0.032
20/68.97 vs. 
11/15.07 0.000 21/34.43 vs. 10/23.26 0.222
Were the methods used 
to combine the findings 
of studies appropriate?
66/64.71 32/58.18 vs. 26/81.25 0.019
37/63.79 vs. 
29/65.91 0.826
28/60.87 vs. 
38/67.86 0.465
18/62.07 vs. 
48/65.75 0.727 39/63.93 vs. 29/67.44 0.713
Was the likelihood of 
publication bias assessed? 16/15.69
3/5.45 vs. 
8/25.00 0.017
10/17.24 vs. 
6/13.64 0.622
5/10.87 vs. 
11/19.64 0.228
6/20.69 vs. 
10/13.70 0.383 8/13.11 vs. 9/20.93 0.291
Was the conflict of 
interest stated? 62/60.78
38/69.09 vs. 
22/68.75 0.974
37/63.79 vs. 
25/56.82 0.477
29/63.04 vs. 
33/58.93 0.673
11/37.93 vs. 
51/69.86 0.001 35/57.38 vs. 27/62.79 0.581
Table 6.  Subgroup analyses of methodological quality assessment (n/%). *6 studies published in journals 
with no associated impact factor. #Based on the median division of number of included NMAs, December 31st 
2013 is the cut-off point. &2 adjusted indirect comparisons also were conducted using Bayesian framework.
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according to the statistical analysis section of PRISMA extension statement, and were extracted by two independ-
ent reviewers (LG, JZ), and conflicts were resolved by a third reviewer (J-HT, or K-HY):
•	 Was traditional meta-analysis conducted?
•	 Were summary measures reported?
State the principal summary measures (e.g., risk ratio, odd ratio, mean difference, hazard ratio). Also describe 
the use of additional summary measures assessed, such as treatment rankings (e.g., treatment rankings, best, 
or surface under the cumulative ranking curve (SUCRA) values), shape and scale parameters for survival 
data29.
•	 Planned methods of analysis, this should include:
Was a Bayesian or a frequentist framework used?
What was the model used? (random-effects model, fixed-effect model, others, or not report).What was the 
method used to undertake the indirect comparisons30?
Was the model code presented or source cited in Bayesian analyses? (not provided, manuscript, online sup-
plement, external web site, reference, or others).
Was the model fit assessed? (e.g., residual deviance31, deviance information criterion31, other, not reported).
Was handling of multigroup trials reported?
Was selection of prior distributions in Bayesian analyses described?
Was the convergence in Bayesian analyses assessed32?
Was the heterogeneity in traditional meta-analysis assessed and how to handle the heterogeneity33?
Was the heterogeneity in the entire network of NMA assessed and how to handle the heterogeneity34?
Was the transitivity/similarity in NMA assessed35?
•	 Were the inconsistency assessed and how to handle the inconsistency36?
•	 Was the publication or reporting bias assessed37?
•	 Additional analyses included:
Category Overall score
AMSTAR-score
Statistic P-value8.00 (6.00, 8.25)
Year of publication
1.194 0.232
2006~2013 (n = 58) 7.00(5.00, 9.00)
2014~2015 (n = 44) 8.00(6.25, 8.00)
Country of corresponding author I
2.557 0.465
East Asia (n = 34) 8.00(7.00, 9.00)
Europe (n = 47) 7.00(5.00, 8.00)
North America (n = 18) 7.00(5.00, 8.25)
Others (n = 3) 7.00(6.00, 7.00)
Country of corresponding author II
2.272 0.023
China (n = 29) 8.00(7.00, 9.00)
Others (n = 73) 7.00(5.00, 8.00)
Impact factors of SCI
5.503 0.239
Not SCI (n = 15) 8.00(6.00, 8.00)
0.0–2.0 (n = 6) 5.00(2.00, 9.00)
2.0–5.0 (n = 49) 7.00(5.00, 8.00)
5.0–10.0 (n = 22) 8.00(6.00, 9.00)
≥ 10.0 (n = 10) 7.00(7.00, 9.00)
Funding source
1.512 0.469
Not report (n = 42) 8.00(6.00, 9.00)
Unfunded (n = 14) 7.50(7.00, 8.00)
Funding-supported (n = 46) 7.00(5.00, 8.25)
Method
1.601 0.109
Indirect comparison (n = 41) 7.00(3.50, 8.00)
Bayes (n = 61) 8.00(6.00, 9.00)
Categories of disease
5.649 0.342
Non-small cell lung cancer (n = 19) 8.00(7.00, 9.00)
Breast cancer (n = 12) 7.00(4.25, 8.00)
Renal cell carcinoma (n = 7) 6.00(5.00, 8.00)
Colorectal cancer (n = 6) 7.50(6.00, 10.25)
Gastric cancer (n = 6) 8.00(7.00, 9.00)
Others (n = 52) 7.50(5.25, 8.75)
Table 7.  The association of total AMSTAR-score and selected general characteristics [median (IQR)].
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Was a sensitivity analysis performed? (e.g., excluding studies, alternative prior distributions for Bayesian anal-
yses, alternative formulations of the treatment network).
Was subgroup analysis or meta-regression performed?
•	 Was the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool used to 
assess quality of evidence26?
Methodological quality assessment. There were no consensuses to assess the methodological quality 
of NMAs. We assessed the methodological quality of included NMAs using a modified AMSTAR checklist. This 
checklist included 11 items, with possible responses of “Yes” (item/question fully addressed), “No” (item/ques-
tion not addressed), “Cannot answer” (not enough information to answer the question), and “Not applicable”. 
Two reviewers (XQ, G-QP) independently extracted data, and conflicts were resolved by a third reviewer (LG, or 
J-HT). The total score using AMSTAR was obtained by summing one point for each “yes” and no points for any 
other responses (“no”, “Cannot answer” and “Not applicable”), ranging from 0 to 11. In our study, three of the 11 
items were slightly modified as follows (Appendix 3):
•	 “Was an ‘a priori’ design provided?” was amended to “Was the research question (i.e., research purpose, inclu-
sion and exclusion criteria) clarified?”
The reason for this modification was that only a small minority of published non-Cochrane reviews reported 
a protocol38. Where a protocol providing this information was available, the answer to this question would be 
“Yes”. Where no protocol was available but detailed information about research purpose and inclusion and 
exclusion criteria (patients, interventions, comparators, outcome, and study design) were supplied, we also 
considered answer this question “Yes”.
•	 “Was a list of studies (included and excluded) provided?” was amended to “Were a list of included studies and 
flow diagram provided?”
The reason for this modification was that most of published systematic reviews did not provide a list of 
excluded studies. Where a list of included studies and flow diagram of literature selection were provided (as 
references, electronic link, or supplement), we considered answer this question “Yes”.
•	 Were the methods used to combine the findings of studies appropriate?
For pairwise meta-analysis, we scored “Yes” if they mentioned or described heterogeneity and reported how 
to handle heterogeneity. For NMA, the following factors should be taken into consideration except heteroge-
neity, but not be limited to: summary measures, model used, model fit, prior distributions (Bayesian analysis), 
convergence (Bayesian analysis), and inconsistency.
Statistical analysis. Quantitative data were summarised by medians and interquartile range (IQR), and 
categorical data summarised by numbers and percentages. The association between methodological quality and 
following characteristic variables was explored using the Mann-Whitney U test and Kruskai-Wallis test: journal 
impact factor, year of publication, funding source, country of corresponding author, type of NMAs, and catego-
ries of disease. Moreover, the subgroup analyses for statistical reporting were performed according to journal 
impact factor (high vs. low impact factors) and year of publication (older vs. recent studies). Proportion results 
were analysed by Chi-square test using STATA version 12.039. All tests were two sided, and P ≤ 0.05 was consid-
ered statistically significant.
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